Response Genetics, Inc. (RGDXQ) 股价，以美元计价

Response develops, manufactures and markets rapid onsite diagnostic tests for use with its RAMP platform for clinical, biodefense and environmental applications. RAMP represents a unique paradigm in diagnostics that provides reliable, quality results in minutes. The RAMP platform consists of a reader and single use disposable test cartridges and has the potential to be adapted to any other medical and nonmedical immunoassay based test currently performed in laboratories. Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, thromboembolism and infectious diseases. In the nonclinical market, RAMP tests are currently available for the environmental detection of West Nile Virus antigen and for Biodefense applications including the rapid onsite detection of anthrax, smallpox, ricin and botulinum toxin.